细辛脑联合糜蛋白酶雾化吸入佐治喘憋性肺炎临床分析

Clinical analysis of atomization inhalation by asarone and chymotrypsin on asthmatic pneumonia

目的观察细辛脑联合糜蛋白酶雾化吸入治疗小儿喘憋性肺炎的临床效果。方法选择喘憋性肺炎患儿108例,随机分为实验组与对照组各54例,两组均给予常规综合治疗,实验组在此基础上给予细辛脑联合糜蛋白酶雾化吸入。比较两组典型症状消失的时间、7 d有效率及住院时间。结果实验组典型症状消失的时间明显低于对照组(t=4.68,P<0.01),且实验组所有病例在治疗期间均未见任何毒副作用;实验组治疗7 d有效率明显高于对照组(χ2=4.15,P<0.05);实验组平均住院天数明显较对照组缩短(t=5.02,P<0.01)。结论应用细辛脑联合糜蛋白酶雾化吸入佐治喘憋性肺炎效果显著,值得临床推广使用。

Objective To explore the clinical effect of Atomization Inhalation by Asarone and Chymotrypsin on Asthmatic Pneumonia. Methods One hundred and eight eases of children with asthmatic pneumonia were chosed as a review, divide into experimental group and the Control group randomly, each group had 54 cases. Two groups were both given conventional treatment,and the experimental group were given atomization inhalation by asarone and chymotrypsin in addition.To compare the typical symptoms disappear time,7 days efficient and length of hospital stay. Results The typical symptoms disappear time of experimental group was significantly lower than the control group（t = 4.68,P 〈 0.01 ）, no side effects occurred on all cases during treatment; the efficient treatment of 7 days of experimental group were higher than that of control group （X2=4.15, P 〈 0.05）;the average hospitalization days of experimental group were shorter than that of control group （t = 5.02,P 〈 0.01）. Conclusion Atomization inhalation by asarone and chymotrypsin on asthmatic pneumonia have remarkable curative effect,it is worth for clinical promotion use.